Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Davita Inc (DVA) vs iShares China Large-Cap ETF (FXI) Price & Performance

Davita IncTrade
iShares China Large-Cap ETFTrade

Price performance (Past 24H)

Key statistics

Davita Inc vs iShares China Large-Cap ETF — how do they compare? Davita Inc trades at $178.34 (market cap $11.72B), while iShares China Large-Cap ETF trades at $35.3. The key difference: Davita Inc is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals.

DVAFXI
Market Cap
$11.72B
Sector
Health
52-Week High
$240.96$41.75
52-Week Low
$103.87$31.59
Enterprise Value
$24.44B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Davita Inc

DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.

The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.

iShares China Large-Cap ETF

FXI, the iShares China Large-Cap ETF, trades at $36.17, up 0.61% on the day, with a bullish technical signal driven by moving averages. The ETF benefits from China's strong export data and state-backed economic support, though key financial ratios are not disclosed in the provided data. Recent news highlights China's AI and manufacturing strength as positive catalysts.

Outlook is cautiously optimistic given bullish technicals and macroeconomic tailwinds, but risks include U.S.-China tensions and reliance on financials-heavy exposure. The dividend announcement for 2026 provides income appeal, yet investors face volatility from geopolitical and regulatory uncertainties.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Davita Inc

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

Read more on DVA

About iShares China Large-Cap ETF

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.

Read more on FXI